We previously demonstrated signi®cant therapeutic activities associated with adenoviral vector-mediated Herpes Simplex Virus/thymidine kinase (AdHSV-tk) with ganciclovir (GCV) in situ gene therapy in the RM-1 orthotopic mouse prostate cancer model and interleukin-12 (AdmIL-12) in situ gene therapy in the RM-9 orthotopic mouse prostate model for prostate cancer. In both protocols, local cytotoxicity and activities against pre-established lung metastases were demonstrated. To test whether combined AdHSV-tk GCV IL-12 gene therapy would lead to enhanced therapeutic effects when compared to either treatment alone, we used RM-9 mouse prostate cancer cells in both orthotopic and preestablished lung metastases models of prostate cancer. Combined treatment with a single injection of optimal doses of AdHSV-tk GCV or AdmIL-12 led to signi®cantly increased suppression of orthotopic tumor growth. IL-12 gene therapy alone was more effective than AdHSV-tk GCV in suppressing spontaneous lymph node metastases and pre-established lung metastases but combination gene therapy did not result in additional anti-metastatic activities. Combination gene therapy also did not achieve signi®cantly better animal survival compared to AdHSV-tk GCV or AdmIL-12 alone. Analysis of localized antitumor activities demonstrated that AdHSV-tk GCV therapy induced higher levels of necrosis compared to AdmIL-12 or combination therapy. However, both treatments alone and combination therapy produced similar increases in apoptotic index. To address the possible mechanisms of locally co-operative cytotoxic activities, we analyzed the systemic natural killer (NK) response and the numbers of tumor-in®ltrating immune cells using quantitative immunohistochemical analysis. AdHSV-tk GCV therapy alone led to detectable increases in iNOS-positive cells, CD4 and CD8 T-cells and moderately increased numbers of F4/80 (macrophage selective)-positive cells within treated tumors. In contrast, AdmIL-12 elicited a highly robust pattern of tumor in®ltration for all four of these immune cells that was in general mimicked by combination therapy. Further analysis of the accumulation of transforming growth factor-b1 (TGF-b1) immunohistochemical staining demonstrated that AdHSV-tk GCV treatment, but not AdmIL-12 treatment, produced cancer cell-associated increases in this cytokine relative to control Ad-b-gal injections. Interestingly, local injection with AdHSV-tk GCV induced signi®cant splenocyte-derived NK cell cytolytic
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Introduction
Over recent years, we have completed preclinical studies designed to assess the ef®cacy and toxicity of adenoviral vector-mediated in situ Herpes Simplex Virus-thymidine kinase (HSV-tk) with ganciclovir (GCV) in situ gene therapy using both in vitro and in vivo prostate cancer models. We were able to document extensive cytotoxic activities in human prostate cancer cell lines in vitro and in subcutaneous and orthotopic tumors generated using RM-1 mouse prostate cancer cells. 1 In further studies using orthotopic RM-1 models, we were also able to demonstrate signi®cant locally cytotoxic effects that led to enhanced survival and to demonstrate systemic antimetastatic activities. 2 Encouraged by these ef®cacy studies, we then addressed the local toxicity of Ad-HSV-tk GCV gene therapy and systemic distribution of the adenoviral vector following transduction into the mouse prostate cancer gland. In general, these studies indicated that the in¯ammatory and distribution pro®le were within acceptable limits for proceeding to human trials. We subsequently embarked upon a phase I clinical trial that was recently completed. This trial involved a single course of AdHSV-tk GCV gene therapy in patients with local recurrence of prostate cancer following irradiation therapy but without any clinical evidence of systemic disease. The results indicated that AdHSV-tk in-situ gene therapy was safe and unexpectedly there were some signs of ef®cacy. 3 Our strategy was to proceed directly with more direct immunomodulatory gene therapy protocols initially in preclinical analysis and ultimately in clinical trials. We initially selected IL-12 based on its widespread immune stimulatory and antitumor effects and proceeded with adenoviral vector-mediated IL-12 in situ gene therapy protocols in the RM-9 mouse prostate cancer model system. Our initial report indicated that a single injection of AdmIL-12 alone into orthotopically generated mouse prostate cancers could generate signi®cant localized cytotoxic activities mediated by a variety of in®ltrating immune cells including NK cells, T-cells, and macrophages. These activities lead to enhanced survival in treated animals as well as to signi®cant suppression of pre-established lung metastases. 4 These studies have led us to the obvious consideration of testing combination AdHSV-tk GCV IL-12 gene therapy protocols in our preclinical models. Combination gene therapy has recently become an area of focus for many groups and early experimental data indicate that speci®c gene therapy strategies involving combinations of immunostimulatory molecules can generate additive and/or synergistic therapeutic effects. 5 ± 7 For example, in a colon cancer metastasis model, combination AdHSVtk GCV IL-2 or AdHSV-tk GCV GM 7 CSF gene therapy was shown to enhance tumor regression and survival when compared to either treatment alone. 5, 6 In general, the concept of using AdHSV-tk GCV AdmIL-12 as a combination therapy is attractive for many malignancies including prostate cancer. The activities of AdHSV-tk GCV could not only generate signi®cant cytotoxic activities locally and, thereby, contribute to a therapeutic response, but also potentially maximize tumor antigen presentation through its necrotic and apoptotic effects. 1, 8, 9 The addition of adenoviral vector-delivered locally active IL-12 could potentially maximize the in®ltration of speci®c immune cells and cause them to be activated and mature into active effectors and thus effectively co-operate with AdHSVtk GCV gene therapy. In this study we evaluated the speci®c in®ltration of immune cells within orthotopic mouse prostate cancer under single AdHSV-tk GCV or AdmIL-12 in situ gene therapy and combined treatment conditions. More extensive immune cell in®ltrates were found to be associated with AdmIL-12 and combination gene therapy compared to AdHSV-tk GCV as a single treatment. Depletion of NK cells in vivo demonstrated that these cells contributed to early local tumor growth suppression by AdHSV-tk GCV but not AdmIL-12. Our studies further demonstrated that NK cell activities were predominantly responsible for activities against pre-established metastases associated with both gene therapy protocols.
Materials and methods

Cells and adenovirus
The mouse prostate cancer cell line RM-9 was derived from a primary prostate tumor induced in the Zipras/ myc-9 infected mouse prostate reconstitution (MPR) model system using C57BL/6 mice as previously described. 10,11 Cells were grown in Dulbecco's modi®ed Eagle media (DMEM) with 10% fetal bovine serum, 10 mM HEPES, penicillin (100 U/ml) and streptomycin (100 mg/ml), passaged by trypsinization with 0.025% trypsin, and maintained with routine media changes.
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An adenoviral vector expressing mouse IL-12 (AdmIL-12) was provided by Dr Frank Graham and propagated as previously described. 4 The adenoviral vector expressing the HSV-tk gene, AdHSV-tk has also been previously described. 1 As controls we used either AdHSV-tk vector followed by PBS instead of ganciclovir (GCV) or Ad/ CMV/bgal. 12 In vivo gene therapy For orthotopic tumor inoculation the right or left lobe of the dorso-lateral prostate of syngeneic C57/BL6 mice was injected with 5000 RM-9 cells in a volume of 10 ml. To determine a target therapeutic viral dose, escalating viral doses from 5610 7 to 3610 8 plaque forming units (PFU) of AdmIL-12 were directly injected into established prostate tumors at a time (7 ± 8 days post tumor cell inoculation) when the tumor volume was approximately 5 ± 15 mm. 3 Ad/CMV/bgal was used as a control vector at 5610 8 PFU. All vector injections were performed as previously described 4 in a volume of 25 ml. Pre-existing lung metastases were established by tail vein injection of 100 000 cells (in 100 ml) at the same time as the orthotopic inoculation of 5000 RM-9 cells into the prostate. On day 6 or 7 post-inoculation animals were randomized to receive in situ orthotopic tumor injections of adenovirus.
Animals were killed on the 14th day post vector injection or at 2, 7, or 14 days after viral injection for kinetic analyses of various biological/therapeutic activities. For survival analysis, animals were evaluated at death, or killed when in distress, as evidenced by lethargy, ruf¯ed fur or weight loss. Sample size was 5 ± 10 mice per treatment group except in the kinetic analyses which was three mice per treatment at each time point. All animals underwent a careful necropsy for gross metastases. The primary tumor and spleen were removed and weighed. The spleen was placed in sterile media until the splenocytes could be harvested in order to perform NK activity assays. In addition the pelvic and retroperitoneal lymph nodes and samples of lung were excised regardless of gross appearance and along with a portion of the primary tumor processed for histological analysis. All tissues were placed in formalin, paraf®n embedded, cut into 5 mm sections, and stained with hematoxylin and eosin (H&E) for histologic examination. Tissues were also frozen in optimal cutting temperature (OCT) compound, cut into 6 mm sections, and ®xed with acetone/methanol for further immunohistochemical staining. Animals with pre-existing metastases were killed on the eighth day after vector injection at which time the lungs were weighed, ®xed in Bouin's ®xative, and visible lung metastases counted with the aid of a dissecting microscope at 106 magni®cation as previously described. 4, 8 To block NK activity mice were injected with 5000 RM-9 cells orthotopically and 100 000 cells via the tail vein. Five days later one group received an intraperitoneal injection of 100 mg of anti-asialo-GM1 serum in 0.15 ml. One day later the mice were operated on and the prostatic tumor injected with vector. Two days later half of the animals were killed to determine tumor wet weight after careful dissection from remaining prostatic tissue, number of lung metastases visible with a dissecting microscope, and NK activity in splenocytes as described above. The rest of the mice received an additional injection of anti-asialo-GM1 serum at day 3 and 6 after vector injection and were then killed on day 8 after vector injection and evaluated as above. As previously demonstrated there was no effect on IL-12 mediated anti-tumor or anti-metastatic activity observed in mice injected with normal mouse IgG instead of anti-asialo-GM1 serum. 4 All mice were maintained in facilities approved by the American Association for Accreditation of Laboratory Animal Care and all animal studies conducted in accordance with the principles and procedures outlined in the National Institutes of Health's Guide for the Care and Use of Laboratory Animals.
In vitro NK assays NK cells were detected by cytolysis of 51 Cr labeled YAC cells by splenocytes obtained from tumor-bearing mice using standard assays. 4 The YAC cell line was obtained from the American Type Culture Collection. The percentage of speci®c lysis was calculated as: (exp cpm 7 spont cpm)/(max cpm 7 spont cpm)6100, where exp cpm represents 51 Cr release from target cells incubated with effector cells, max cpm represents release of radiolabel from target cells in 5% SDS, and spont cpm represents background release of target cells incubated in medium alone.
Quantitative image analysis
Formalin ®xed, paraf®n embedded sections were stained with H&E for routine histological analysis. To determine apoptosis sections of primary tumor tissue were analyzed for DNA fragmentation by the TUNEL technique. 13 The extent of apoptosis was assessed quantitatively via computer assisted image analysis as previously described. 8 The extent of necrosis was also assessed quantitatively on H&E stained slides via computer-assisted range image analysis. 8 For immunohistochemical analyses tissues were snap frozen with liquid nitrogen in Tissue-Tec OCT compound. They were then sectioned and 6 mm slices ®xed on polylysine-coated slides with cold acetone. Immunohistochemical staining was performed using the avidin ± biotin-peroxidase Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA). Primary antibodies were anti-cytokeratin (rabbit polyclonal A0575, Dako Corp, Carpinteria, CA), anti-factor VIII (rabbit polyclonal A0082, Dako), anti-CD4 (clone: H129.19, PharMingen, San Diego, CA), anti-CD8 (clone: 53-6.7, PharMingen), Rat anti-mouse F4/80 antigen (clone C1: A3-1, Serotec, Oxford, UK), which recognizes the mouse F4/80 antigen expressed by macrophages, polyclonal rabbit TGF-b1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), and polyclonal rabbit anti-inducible nitric oxide synthase antibody (Calbiochem, San Diego, CA). Secondary anti-bodies were biotinylated goat anti-rat immunoglobulin (Vector Laboratories, Burlingame, CA) and goat antirabbit immunoglobulin (Vector Laboratories, Burlingame, CA). Sections were developed with 3,3'-diaminobenzidine tetrahydrochloride (Sigma, St. Louismo), counterstained with methylgreen, and permanently mounted. Sections were scored in a blinded manner. Computer assisted image analysis was used to generate the number of immunopositive cells per mm 2 essentially as described previously. 4 Statistical analysis ANOVA, t-test and Mann ± Whitney was used to make comparisons between the means. Kaplan ± Meier survival analyses were compared with Log-rank test (Mantel ± Cox test). All analyses were performed with Statview 4.02 (Abacus Concepts, Berkeley, CA).
Results
Combination AdHSV-tk GCV AdmIL-12 gene therapy signi®cantly enhances local tumor growth relative to single treatment protocols
To determine an optimal concentration of AdmIL-12 for use with AdHSV-tk GCV in regard to tumor growth suppression, we performed a dose escalation study with a ®xed optimal concentration of AdHSV-tk (5610 8 ) PFU and increasing concentrations of AdmIL-12 beginning with 1610 7 PFU/mL. The results indicated that a dose of 1610 8 PFU of AdmIL-12, which we previously demonstrated to be the maximally effective, nontoxic dose in this system, 4 was also able to generate co-operative activities (Figure 1a) , although a dose of 5610 7 PFU of AdmIL-12 was nearly as effective when combined with AdHSV-tk. All gene therapy treatments demonstrated signi®cantly better suppression of tumor weight in comparison to Ad/ CMV/bgal controls and the combination AdHSVtk GCV 12 therapy yielded a signi®cant reduction in local tumor volume in comparison to either AdHSVtk GCV alone (P 0.0007) or AdmIL-12 alone (P 0.033). Dose escalation of AdHSV-tk relative to a ®xed dosage of AdmIL-12 was not done. To further characterize the therapeutic activities of AdHSVtk GCV AdmIL-12 relative to each vector independently, we treated RM-9 tumors with all three protocols as well as an Ad/CMV/bgal control and determined the tumor wet weights over a 14-day growth period (Figure  1b) . The results indicated a statistically signi®cant enhancement of growth suppression by combination AdHSV-tk GCV AdmIL-12 compared to control Ad/ CMV/bgal (P 0.0001) or AdHSV-tk GCV alone (P 0.0407). Although combination therapy appeared to be somewhat better than AdmIL-12 alone this difference did not achieve statistical signi®cance (P 0.1285). The failure to achieve statistical signi®cance in this experiment was likely due to the small sample size (n 3) since signi®cance was achieved with a larger sample size (n 8) by the results presented in Figure 1a .
Combination in situ AdHSV-tk GCV AdmIL-12 gene therapy does not signi®cantly enhance survival
To test for possible enhancement of survival of tumorbearing animals by AdHSV-tk GCV AdmIL-12 combination therapy, we determined mean survival for a series of animals treated with both single and combination gene therapy following a single vector injection. The results indicated improved survival compared to controls but no statistical difference among single AdHSV-tk GCV treatments, AdmIL-12 treatment, or the combination AdHSVtk GCV AdmIL-12 ( Figure 2 ). When data were pooled from multiple experiments including both the experiments in which all four treatments were administered at the same setting as well as previous data using independent AdmIL-12 vector injection, 4 there was still no signi®cant difference between combination AdHSV-tk GCV AdmIL-12 and AdmIL-12 treatment (not shown).
Combination in situ AdHSV-tk IL-12 gene therapy does not further suppress spontaneous lymph node metastases or pre-established lung metastasis beyond AdmIL-12 gene therapy alone
The effectiveness of each gene therapy against spontaneous metastatic activity was assessed by scoring the frequency of pelvic lymph nodes positive for prostate cancer cells as detected by cytokeratin staining. AdmIL-12 and the combination of AdHSV-tk GCV AdmIL-12 were effective at suppressing spontaneous lymph node metastases compared to controls (P 0.001 and 0.008, respectively) (Figure 3a) . AdHSV-tk GCV therapy alone did not have a statistically signi®cant effect on spontaneous lymph node metastases and there was no additive effect of AdHSV-tk GCV AdmIL-12 beyond that of AdmIL-12. A lower dose of AdmIL-12 (5610 7 ) was equally effective at suppression of spontaneous metastases either alone or in combination with AdHSVtk GCV (not shown).
Since we previously demonstrated suppression of preestablished lung metastases in vivo with AdHSV-tk GCV treatment of RM-1 and AdmIL-12 treatment of RM-9 4 mouse prostate cancer cell lines, we tested the ability of combination AdHSV-tk GCV AdmIL-12 gene therapy to enhance suppression of pre-established lung metastases in vivo. Orthotopic tumor cell injections and tail vein injections, to establish lung metastases, were simultaneously performed according to previously described protocols. 4 Seven days post injection, animals were treated with the two individual gene therapies, combination gene therapy as well as an AdHSV-tk control group treated with PBS instead of GCV. The combination gene therapy, as well as AdmIL-12 alone, resulted in signi®-cantly fewer lung metastases per animal compared to the control AdHSV-tk/PBS (P 0.0001) or AdHSV-tk GCV (P 0.0028) (Figure 3b ). However the results indicated that AdHSV-tk GCV did not result in a statistically signi®cant effect against pre-established metastasis in this model and combination AdHSV-tk GCV AdmIL-12 did not further enhance activity against pre-established lung metastases compared to the level of suppression achieved by AdmIL-12 alone (P 0.66).
Analysis of cytotoxic effects in treated tumors
To analyze the biological activities of these single and combination gene therapy treatments, we determined the extent of necrosis by quantitatively assessing the necrotic tumor mass using image analysis systems and the apoptotic index by quantitative TUNEL staining. 1, 13 These quantitative assessments were made on tumors seven days after orthotopic implantation at the time of vector injection (day 0) and at 2, 7 and 14 days following vector injections. Interestingly, the results indicated that AdHSVtk GCV single agent therapy induced more extensive necrosis over time relative to AdmIL-12 alone. Combination therapy induced levels of necrosis similar to that of AdmIL-12 ( Figure 4a ). With regard to induction of apoptosis, a time-dependent induction of apoptosis was observed for all treatments whereas controls maintained a low level of apoptosis (Figure 4b ). There was no 8 PFU while the dose of AdmIL-12 was varied as indicated. AdHSV-tk GCV alone was growth suppressive compared to b-gal controls (P`0.0001) and addition of AdmIL-12 enhanced this effect (P`0.0001 compared to b-gal controls and P 0.0007 compared to AdHSV-tk GCV alone). AdmIL-12 alone at 1610 8 PFU led to signi®cant growth suppression compared to controls as previously reported, 4 but no signi®cant difference compared with AdHSV-tk GCV (P 0.27). Panel (b) In a separate experiment, animals were killed at 2, 7 and 14 days after vector injection and orthotopic tumor weight determined. Vector was injected in a constant volume with optimal vector doses of AdHSV-tk or Ad/CMV-b-gal at 5610
8 PFU and AdmIL-12 at 1610. 8 Shown are mean tumor weight with standard error of the mean (s.e.m.).
Combination HSV-tk GCV IL-12 gene therapy for prostate cancer Y Nasu et al Combination HSV-tk GCV IL-12 gene therapy for prostate cancer Y Nasu et al signi®cant difference between the treatments with regard to induction of apoptosis. To assess the mean vessel density in the tumors we stained sections from tumors on day 14 with Factor VIII antibody. The vessel density was greatest in the control tumors and yet in this study there were no signi®cant differences demonstrated between the treatment and control groups (Figure 4c ).
Quantitative immunohistochemical analysis of immunocytes during the course of treatments
To further analyze the differential therapeutic activities of these gene therapy protocols, we used quantitative immunohistochemistry to compare the numbers of F4/80-positive cells, iNOS positive cells as well as CD4 and CD8 positive T cells in orthotopic prostate tumors at the time of treatment and at days 2, 7 and 14 following injection with Ad/CMV/bgal, AdHSV-tk, AdmIL-12 or the AdHSV-tk AdmIL-12 vector combination. An extensive in®ltration of F4/80 (macrophage selective)-positive cells was observed for AdmIL-12 and combination AdHSV-tk GCV AdmIL-12 gene therapy at 2 days relative to controls (Figure 5a ). In contrast, AdHSV-tk GCV treatment alone generated a relatively small increase in F4/80-positive cells at day 7 relative to controls. With regard to iNOS/positive cells, both AdmIL-12 and combination AdHSV-tk GCV AdmIL-12 generated increased iNOS cell positive numbers at day 7 following therapy relative to AdHSV-tk GCV injection treatment which produced a relatively minor increase at day 7 relative to controls ( Figure 5B ). Analysis of T-cell in®ltrates showed a similar trend, both AdmIL-12 and combination AdHSV-tk GCV AdmIL-12 produced remarkable increases at day 7 for both CD4 positive and CD8 positive T-cells relative to controls (Figure 5c and d) . In contrast, AdHSVtk GCV treatment produced minimal increases in T-cell CD4 or CD8 positive T-cell in®ltration throughout the course of treatment.
Analysis of TGF-b1 in treated orthotopic tumors
To further assess the immunomodulatory potential of these speci®c gene therapy treatments, we analyzed TGF-b1 expression in prostate cancer cells in all treatment groups at 14 days post treatment and compared them to Ad/CMV/bgal treated controls. In Ad/CMV/bgal treated controls, TGF-b1 expression was observed (Figure 6a) . These results are consistent with known TGF-b1 expression activities in both mouse and human prostate cancer cells. 14 ± 17 AdHSV-tk GCV gene therapy, but not AdmIL-12 gene therapy, produced increased focal TGFb1 expression (Figure 6b) . Semi-quantitative analysis of TGF-b1 staining demonstrated that only AdHSV-tk GCV therapy resulted in a signi®cantly increased TGF-b1 immunostaining score compared to controls (Figure 6c ).
NK cell cytolytic activities in splenocytes and tumor in®ltrating lymphocytes
We analyzed spleen-derived and tumor in®ltrating lymphocyte-derived NK cell activities in response to single agent and combination gene therapy through in vitro cell lysis analysis. 4 The kinetic analysis of induction of splenocyte NK activity (Figure 7a ) following AdmIL-12 injections revealed a peak activity at day 2 whereas AdHSV-tk GCV elicited an increased in splenocyte NK activity at day 7. At day 14 following vector injections splenocyte NK activities were similar to pretreatment levels in both single agent treatments. Interestingly, more extensive 
NK activity was present following the combination gene therapy at all time points compared to each of the single gene therapy treatments alone (Figure 7a ). These data may explain in part the enhanced local killing effect over time by combination therapy (see Figure 1) . Tumor in®l-trating lymphocytes were isolated from day 7 tumors treated with each gene therapy protocol and used to measure NK activity (Figure 7b ). These data con®rm that cells with NK-like activity are present within the orthotopic tumor as well as in the circulation (ie spleen). The relative decline in splenocyte-derived NK activity in AdmIL-12 treated animals on day 7 was not observed in tumor in®ltrating lymphocytes.
Effects of inhibition of NK activity on orthotopic tumor growth
As NK activities in splenocytes on day 2 were not increased by AdHSV-tk GCV treatment relative to control Ad/CMV/bgal NK depletion with anti-asialo-GM1 had no effect. In contrast, AdmIL-12 and AdHSV-tk GCV AdmIL-12 treatment resulted in signi®cantly increased NK activities that were completely abrogated by depletion (Figure 8a ). NK depletion completely abrogated the reduction of tumor weight at day 8 following AdHSV-tk GCV treatment. However, NK depletion had no impact on the reduction of tumor weight at day 8 following AdmIL-12 or AdHSV-tk GCV AdmIL-12 treatment indicating that non-NK cell activities were largely responsible for the level of tumor growth suppression achieved at this time point (Figure 8b) . Analyses of pre-established lung metastases in mice with NK cells depleted revealed abrogation of the anti-metastatic effects of orthotopic tumor treatment with AdHSV-tk GCV (Figure 8c ). The anti-metastatic effects of AdmIL-12 or AdHSV-tk GCV AdmIL-12 treatment were mostly, but not completely abrogated suggesting that NK activities were mainly, but not exclusively responsible for these activities.
Discussion
We previously demonstrated that adenoviral vectormediated AdHSV-tk GCV and AdmIL-12 gene therapy independently generated signi®cant local cytotoxic and systemic antimetastatic effects in mouse prostate cancer models. In this study we combined these two approaches to test for possible co-operative activities. Recently speci®c gene combinations have been shown to produce Combination HSV-tk GCV IL-12 gene therapy for prostate cancer Y Nasu et al enhanced therapeutic activities beyond those produced by the genes as single agents in non-prostatic malignancies. 5 ± 7 Some of these combinations have involved immunomodulatory genes. In a metastatic colon cancer model, the combination of AdHSV-tk GCV with IL-2 and/or GM-CSF was shown to produce enhanced therapeutic activities. 5, 6 It has also been demonstrated that p53 and IL-2 can produce synergistic activities that may result in part from the ability of p53 to suppress growth suf®-ciently to allow for the generation and maturation of the immune activities stimulated by IL-2. 18 However, to our knowledge there are no published formal studies of any malignancy that have tested whether the combination of adenoviral vector-mediated HSV-tk GCV and AdmIL-12 can produce co-operative therapeutic effects.
Our group has focused over recent years on developing AdHSV-tk GCV-in situ gene therapy for prostate cancer using preclinical mouse models followed by clinical trials. 1 ± 3,19 We continue to pursue this approach as our early studies have demonstrated signi®cant ef®cacy in preclinical models and a satisfactory toxicity pro®le and some evidence of ef®cacy in humans. 3 The combination of adenoviral vector-mediated AdHSV-tk GCV AdmIL-12 gene therapy for prostate cancer is particularly attractive because of the potential for the initiation of a local immune response generated by AdHSV-tk GCV to be extended by co-transduction of IL-12.
The results of this study indicate co-operative therapeutic effects of combination AdHSV-tk GCV and AdmIL-12 gene therapy. A signi®cant reduction in primary tumor size in response to combination gene therapy compared to AdHSV-tk GCV or AdmIL-12 single gene therapy was observed. Although combination therapy resulted in enhanced suppression of local tumor growth, it did not produce increased animal survival in this model. Based on previous studies which suggested that NK cells are largely responsible for the antitumor effects of adenoviral vector-mediated IL-12 gene therapy 4, 20 we focused on this activity. However, an investigation into other discrete therapeutic end points revealed interesting differences in AdHSV-tk GCV compared to AdmIL-12 gene therapy. AdHSV-tk GCV generated more necrosis than AdmIL-12, yet each of these gene therapy protocols alone produce nearly equivalent amounts of apoptosis in treated tumors. Combination gene therapy did not generate additional cytotoxic activities. During the initial 7 days following vector injection, both AdmIL-12 gene therapy alone and in combination with AdHSV-tk GCV generated increased F4/80-positive and iNOS-positive immune cells (predominantly macrophage morphology) and CD4-positive and CD8-positive T-cells compared to AdHSV-tk GCV gene therapy alone (see Figure 5 ). Interestingly, our results also indicated that splenocyte-derived NK activities induced by combination gene therapy were more pronounced throughout the treatment period compared to the induction achieved by either AdHSVtk GCV or AdmIL-12 gene therapy alone. This pattern of NK induction appeared to result from an optimization effect that sustained the peak AdmIL-12 associated activities at day 2 post treatment beyond the peak AdHSV-tk GCV associated activity at day 7 post treatment. Curiously, in vivo depletion of NK cells abrogated the early growth suppression resulting from AdHSV-tk GCV gene therapy but not of AdmIL-12 or combination gene therapy. However, NK depletion studies demonstrated that these cells were predominantly responsible for the reduction of pre-established lung metastases that resulted from AdHSVtk GCV, AdmIL-12 and combination gene therapy protocols.
Overall our data suggest that activated macrophage and/or T-cells may be responsible for the early locally cytotoxic activities of AdmIL-12 but that NK activities underlie the early local cytotoxicity induced by AdHSVtk GCV. On the other hand, NK cell activities are predominantly responsible for activities against preestablished metastases mediated by both gene therapy treatment alone or in combination. An additional interesting observation is the increased amount of tumor cellassociated focal TGF-b1 expression in AdHSV-tk GCV but not AdmIL-12 treated tumors (see Figure 6 ). We have previously demonstrated that enhanced TGF-b1 is associated with prostate cancer progression 21 ± 23 and it is well established that TGF-b1 can suppress various immune cell functions that include response to IL-12 24, 25 (this is reviewed in reference 26). Therefore, it is conceivable that Figures 1 and 3 the AdmIL-12 and AdHSV-tk GCV AdmIL-12 treatments had the greatest reduction in tumor weight and the number of lung metastases compared to control Ad/CMV/b-gal treated mice, however NK blocking did not affect the local tumor weight of these two groups but did affect the number of lung metastases. NK depletion did affect the tumor weight and lung metastases in the AdHSV-tk GCV only group. Shown are means with s.e.m.
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